Charles River Laboratories Showcases Technology-Driven Capabilities at AACR 2024
01 April 2024 - 11:00PM
Business Wire
Researchers highlight translational services to
optimize drug development programs
Charles River Laboratories International, Inc. (NYSE: CRL)
announced today that its industry-leading team of oncology experts
will attend the American Association for Cancer Research (AACR)
Annual Meeting. Charles River will present technology-driven
capabilities and highlight the latest advancements in
immuno-oncology, in vitro assays, and more. The meeting is taking
place from April 5-10, 2024, at the San Diego Convention Center in
San Diego, California.
Charles River Launches New Tools & Services to Support
Oncology Research Charles River is showcasing an expanding
portfolio of end-to-end cancer research tools and services,
including:
- The Apollo™ Price Estimator, a new application that enables
seamless generation of oncology study design, simplifies
preclinical drug development by allowing clients to quickly
generate price estimates.
- The Cancer Model Database, a tool that unlocks the ability to
access different assays and comprehensive, well-characterized
models for oncology drug development.
- Charles River is also expanding its cell sourcing offering to
include same-day delivery of fresh leukopaks from its collection
centers into the Cambridge and Greater Boston area as well as the
San Diego biohub.
During the AACR Annual Meeting, the Charles River team will host
a spotlight session and present over 20 scientific posters,
including:
Spotlight Session: PDX: Predictive Tumor Models to Accelerate
your Preclinical Research In Vivo, In Vitro and In Silico
Sunday, April 7, 1:30-2:30 p.m., Sails Pavilion Theater B
Charles River, Cypre Inc., and Aitia will come together to
discuss the use of breakthrough technologies, such as PDX 3D tumor
models and Digital Twins, in the process of identifying optimal
drug candidates. The session will also cover the use of PDX-based
in vitro 3D platforms in the context of the FDA Modernization Act
and different in vivo screening formats. Featured speakers
include:
- Julia Schueler, Therapeutic Area Lead, Charles River
- Isabelle Caffry, Senior Director of Strategy and Corporate
Development, Aitia
- Kolin Hribar, CEO, Cypre
Poster #2714: Developing an mRNA Encoded Therapeutic Antibody
Platform to Simplify Manufacturing and Reduce Time to Clinic
Monday, April 8, 1:30-5:00 p.m., Section 6
The production of therapeutic antibodies entails costly
manufacturing processes, intricate purification methods, and
extensive stability optimization, which contribute to elevated
treatment expenses. Charles River’s poster will discuss the use of
mRNA-based approaches to produce therapeutic antibodies in vivo,
offering a promising strategy for solid tumor treatment,
potentially reducing costs and improving biologic development.
Poster #4186: Development of an Orthotopic A549 Lung
Carcinoma Model in CD34+ Humanized NCG Mice and Response to
Treatment with Paclitaxel and Pembrolizumab Tuesday, April 9,
9:00-12:30 p.m., Section 9
Translational in vivo models are critical to expediting the
discovery of new treatments for lung cancer. In response to the
growing demand for humanized models that can generate translatable
outcomes, Charles River demonstrates the use of an orthotopic lung
carcinoma model in humanized mice (HuCD34 NCG) to evaluate the
activity of paclitaxel and pembrolizumab as single and combination
agents.
To learn more about Charles River’s research tools and services
portfolio, visit booth #1121 at the AACR Annual Meeting
2024. A full schedule of Charles River’s activities and reprints of
each poster will be available online, and more content exploring
topics discussed at the meeting will be shared on the Eureka
Blog.
Approved Quotes
- “Our expert team of oncology researchers here at Charles River
is committed to supporting clients across the R&D continuum,
from basic research to IND and every stage in between. We look
forward to showcasing innovative technology and digitally driven
approaches to cancer research at the AACR Annual Meeting.” – Aidan
Synnott, Corporate Vice President, Global Discovery Services,
Charles River
- “In the dynamic landscape of oncology research, the pursuit of
innovative solutions for predictive screening is imperative.
Cypre’s proprietary 3D tumor microenvironment models platform
expands Charles River’s oncology portfolio and offers our clients
seamless, high-content analysis screening for their cancer
immunotherapy and targeted therapy.” – Kolin Hribar, PhD, CEO &
Founder, Cypre Inc.
- “Aitia and Charles River's joint effort to pioneer PDX Digital
Twins stands at the forefront of a transformative shift in oncology
research, aligning with the industry’s commitment to reduce
reliance on traditional animal models. By integrating breakthrough
technologies like PDX-based in vitro 3D platforms and Digital
Twins, our collaborative efforts represent a significant leap
towards advancing next-generation, in vivo oncology research across
multiple cancer types.” – Isabelle Caffry, Senior Director of
Strategy and Corporate Development, Aitia
About Charles River Charles River provides essential
products and services to help pharmaceutical and biotechnology
companies, government agencies and leading academic institutions
around the globe accelerate their research and drug development
efforts. Our dedicated employees are focused on providing clients
with exactly what they need to improve and expedite the discovery,
early-stage development and safe manufacture of new therapies for
the patients who need them. To learn more about our unique
portfolio and breadth of services, visit www.criver.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240401996705/en/
Investor: Todd Spencer Corporate Vice President, Investor
Relations 781.222.6455 todd.spencer@crl.com
Media: Amy Cianciaruso Corporate Vice President, Chief
Communications Officer 781.222.6168 amy.cianciaruso@crl.com
Charles River Laboratories (NYSE:CRL)
Historical Stock Chart
From May 2024 to Jun 2024
Charles River Laboratories (NYSE:CRL)
Historical Stock Chart
From Jun 2023 to Jun 2024